Maarten Penning

Maarten Penning joined the EuroBio Scientific Group with the acquisition of GenDx. He has a long experience in all aspects of the development and commercialization of in-vitro diagnostic products and services.

After obtaining his PhD at the Academic Medical Center in Amsterdam, Maarten built his career in science-driven, small scale biotech companies which were active in the field of DNA diagnostics. After a focus on cancer diagnostics within Primagen, he moved to OncoMethylome Sciences (now MDxHealth). There, Maarten was managing the site in Amsterdam where assay development took place, as well as service testing for clinical studies of multiple large pharma companies. Under his supervision, ISO 13485:2003 certification and ISO 17025:2005 accreditation were obtained and production facilities for kit manufacturing were set up. In 2010 Maarten joined GenDx, where he became Chief Technology Officer (CTO) and deputy CEO as of 2016. In these roles, Maarten was instrumental in initiation of new  products, which have now evolved in being the most relevant commercial products, as well as in-licensing and purchasing of product lines from third parties.  

Per July 1st 2023, Maarten has taken on the roles of General Manager of GenDx and CTO in the Executive Committee of the Eurobio Scientific Group.

‍